phosphorylcholine has been researched along with Soft Tissue Neoplasms in 2 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter Phase II study was performed to evaluate the clinical activity of an initial loading (150 mg every 6 hours x 4 doses) dose followed by continuous daily oral dosing (100 mg/day) of perifosine in patients with advanced soft tissue sarcomas (STSs)." | 9.12 | Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. ( Bailey, HH; Erlichman, C; Ettinger, DS; Fracasso, PM; Mahoney, MR; Maples, WJ; Okuno, SH; Traynor, AM, 2006) |
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 9.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| "A multicenter Phase II study was performed to evaluate the clinical activity of an initial loading (150 mg every 6 hours x 4 doses) dose followed by continuous daily oral dosing (100 mg/day) of perifosine in patients with advanced soft tissue sarcomas (STSs)." | 5.12 | Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. ( Bailey, HH; Erlichman, C; Ettinger, DS; Fracasso, PM; Mahoney, MR; Maples, WJ; Okuno, SH; Traynor, AM, 2006) |
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 5.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, HH | 1 |
| Mahoney, MR | 1 |
| Ettinger, DS | 1 |
| Maples, WJ | 1 |
| Fracasso, PM | 1 |
| Traynor, AM | 1 |
| Erlichman, C | 1 |
| Okuno, SH | 1 |
| Verweij, J | 1 |
| Krzemieniecki, K | 1 |
| Kok, T | 1 |
| Poveda, A | 1 |
| van Pottelsberghe, C | 1 |
| van Glabbeke, M | 1 |
| Mouridsen, H | 1 |
2 trials available for phosphorylcholine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Hum | 2006 |
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholin | 1993 |